Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Warnex, Inc.
The field of women's health is one of the most progressive medical technology sectors in the US, driven by the aging population, diagnostic advances in deadly ovarian and colorectal cancer, and medical device innovations in gynecologic and urogynecologic disease management, including a shift toward minimally invasive surgery (MIS) techniques and robotics and the addition of a new field: bariatric gynecology. At the WH 2.0 Consensus Conference on Women's Health, held recently in Los Angeles, experts agreed that advances in medical technology are promising better detection and treatment of a host of diseases impacting both premenopausal and postmenopausal women. However, challenges remain in managing obesity-related disease and improving screening for often-undetected cancers in women.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
Brief summaries of recent medtech market and industry developments. This month we cover CE mark approval for Abbott's Absorb bioresorbable stent, rumors about a takeover of Smith & Nephew, and J&J's cancer detection partnership with Veridex.
- Laboratory Testing Services
In Vitro Diagnostics
- Chemistry, Immunoassay
- Hematology, Coagulation
- Molecular Diagnostics & Genetic Testing
- Therapeutic Drug Monitoring